如何开展个性化癌症疗法的临床试验。
How to Conduct Clinical Trials of Personalized Cancer Therapies.
机构信息
Department of Medicine, Division of Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
Department of Medicine, Division of Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
出版信息
Eur Urol Focus. 2022 May;8(3):667-669. doi: 10.1016/j.euf.2022.05.003. Epub 2022 Jun 3.
Abstract
We identified three important principles to guide clinical trials of personalized cancer therapies: (1) incorporation of developments in molecular cancer biology in trial design; (2) inclusion of biomarkers to guide rational therapy; (3) use of innovative trial designs.
摘要
我们确定了指导个性化癌症治疗临床试验的三个重要原则
（1）在试验设计中纳入分子癌症生物学的发展；（2）纳入生物标志物以指导合理治疗；（3）使用创新的试验设计。
相似文献
1
How to Conduct Clinical Trials of Personalized Cancer Therapies.如何开展个性化癌症疗法的临床试验。
Eur Urol Focus. 2022 May;8(3):667-669. doi: 10.1016/j.euf.2022.05.003. Epub 2022 Jun 3.
2
Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments.将生物标志物评估纳入新型临床试验设计：实现脑肿瘤治疗的个体化。
Curr Oncol Rep. 2011 Feb;13(1):42-9. doi: 10.1007/s11912-010-0144-x.
3
Advancing cancer drug development through precision medicine and innovative designs.通过精准医学和创新设计推进癌症药物研发。
J Biopharm Stat. 2018;28(2):229-244. doi: 10.1080/10543406.2017.1402784. Epub 2017 Nov 27.
4
Reinventing clinical trials: a review of innovative biomarker trial designs in cancer therapies.重新构想临床试验：癌症治疗中创新生物标志物试验设计的回顾。
Br Med Bull. 2015 Jun;114(1):17-27. doi: 10.1093/bmb/ldv011. Epub 2015 Apr 28.
5
Genomic Alteration-Driven Clinical Trial Designs in Oncology.肿瘤学中基于基因组改变的临床试验设计。
Ann Intern Med. 2016 Aug 16;165(4):270-8. doi: 10.7326/M15-2413. Epub 2016 May 24.
6
Clinical trial designs for testing biomarker-based personalized therapies.基于生物标志物的个体化治疗的临床试验设计。
Clin Trials. 2012 Apr;9(2):141-54. doi: 10.1177/1740774512437252. Epub 2012 Mar 7.
7
Implementing personalized cancer genomics in clinical trials.在临床试验中实施个体化癌症基因组学。
Nat Rev Drug Discov. 2013 May;12(5):358-69. doi: 10.1038/nrd3979.
8
Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial.启动和开展个性化癌症治疗试验的挑战：来自全球创新网络（WIN）联盟试验WINTHER的观点
Ann Oncol. 2015 Aug;26(8):1791-8. doi: 10.1093/annonc/mdv191. Epub 2015 Apr 23.
9
An overview of the design and conduct of the BATTLE trials.BATTLE试验的设计与实施概述。
Chin Clin Oncol. 2015 Sep;4(3):33. doi: 10.3978/j.issn.2304-3865.2015.06.07.
10
Methodological and practical challenges for personalized cancer therapies.个性化癌症治疗的方法学和实践挑战。
Nat Rev Clin Oncol. 2011 Mar;8(3):135-41. doi: 10.1038/nrclinonc.2011.2.
本文引用的文献
1
Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.尿路上皮癌分子亚型对新辅助化疗的不同反应。
Eur Urol. 2022 May;81(5):523-532. doi: 10.1016/j.eururo.2021.10.035. Epub 2021 Nov 13.
2
Reconciling differences in impact of molecular subtyping on response to cisplatin-based chemotherapy.协调分子亚型对顺铂化疗反应影响的差异。
Nat Commun. 2021 Aug 10;12(1):4833. doi: 10.1038/s41467-021-24837-8.
3
Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience.成纤维细胞生长因子受体 3 改变与转移性尿路上皮癌对免疫检查点抑制的反应：真实世界经验。
Br J Cancer. 2021 Oct;125(9):1251-1260. doi: 10.1038/s41416-021-01488-6. Epub 2021 Jul 22.
4
20 years of precision medicine in oncology.肿瘤学领域20年的精准医疗
Lancet. 2021 May 15;397(10287):1781. doi: 10.1016/S0140-6736(21)01099-0.
5
Developing Precision Medicine for Bladder Cancer.开发膀胱癌精准医学。
Hematol Oncol Clin North Am. 2021 Jun;35(3):633-653. doi: 10.1016/j.hoc.2021.02.008. Epub 2021 Apr 10.
6
Biomarker approach harnessed in trials of personalized medicine for bladder cancer.生物标志物方法在膀胱癌个性化医疗试验中得到应用。
Nat Med. 2021 May;27(5):761-763. doi: 10.1038/s41591-021-01300-1.
7
Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial.分子亚型分类和基因组分析在难治性转移性三阴性乳腺癌的精准医学中扩展：FUTURE 试验。
Cell Res. 2021 Feb;31(2):178-186. doi: 10.1038/s41422-020-0375-9. Epub 2020 Jul 27.
8
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.肌肉浸润性膀胱癌的共识分子分类。
Eur Urol. 2020 Apr;77(4):420-433. doi: 10.1016/j.eururo.2019.09.006. Epub 2019 Sep 26.
9
Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols.系统评价篮子试验、伞式试验和平台试验：主方案的全景分析。
Trials. 2019 Sep 18;20(1):572. doi: 10.1186/s13063-019-3664-1.
10
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.肌层浸润性膀胱癌的综合分子特征分析
Cell. 2018 Aug 9;174(4):1033. doi: 10.1016/j.cell.2018.07.036.
Zotero 插件